Corcept Therapeutics Incorporated (CORT) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $111.85 (+0.93%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 22, 2026 | Swayampakula Ramakanth | H.C. Wainwright | $105.00 | -6.1% |
| Jan 2, 2026 | Swayampakula Ramakanth | H.C. Wainwright | $90.00 | -19.5% |
| Jan 2, 2026 | Edward Nash | Canaccord Genuity | $99.00 | -11.5% |
| Dec 16, 2025 | Ashwani Verma | UBS | $95.00 | -15.1% |
| May 6, 2025 | Joon Lee | Truist Financial | $135.00 | +20.7% |
| May 6, 2025 | Swayampakula Ramakanth | H.C. Wainwright | $145.00 | +29.6% |
| Oct 18, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $80.00 | -28.5% |
| Sep 30, 2024 | Joon Lee | Truist Financial | $76.00 | -32.1% |
| Aug 15, 2024 | Edward Nash | Canaccord Genuity | $78.00 | -30.3% |
| Jul 30, 2024 | David Amsellem | Piper Sandler | $38.00 | -66.0% |
| Jul 30, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $45.00 | -59.8% |
| Jun 12, 2024 | Edward Nash | Canaccord Genuity | $38.00 | -66.0% |
| Jun 10, 2024 | David Amsellem | Piper Sandler | $35.00 | -68.7% |
| Jun 4, 2024 | Joon Lee | Truist Financial | $65.00 | -41.9% |
| May 2, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $40.00 | -64.2% |
Top Analysts Covering CORT
CORT vs Sector & Market
| Metric | CORT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.23 | 2.25 | 2.42 |
| Analyst Count | 13 | 8 | 18 |
| Target Upside | +11.2% | +16187.2% | +19.5% |
| P/E Ratio | 314.74 | 3.49 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $221M | $235M | $247M | 2 |
| 2026-12-31 | $247M | $263M | $276M | 3 |
| 2027-03-31 | $215M | $228M | $240M | 3 |
| 2027-06-30 | $259M | $275M | $289M | 2 |
| 2027-09-30 | $276M | $294M | $309M | 2 |
| 2027-12-31 | $293M | $312M | $327M | 3 |
| 2028-12-31 | $1.43B | $1.53B | $1.69B | 5 |
| 2029-12-31 | $1.99B | $2.12B | $2.34B | 2 |
| 2030-12-31 | $2.40B | $2.56B | $2.83B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $0.13 | $0.14 | $0.15 | 1 |
| 2026-12-31 | $0.25 | $0.27 | $0.29 | 2 |
| 2027-03-31 | $-0.01 | $-0.01 | $-0.01 | 2 |
| 2027-06-30 | $0.24 | $0.26 | $0.28 | 1 |
| 2027-09-30 | $0.33 | $0.36 | $0.38 | 1 |
| 2027-12-31 | $0.38 | $0.41 | $0.44 | 2 |
| 2028-12-31 | $2.15 | $2.89 | $4.09 | 3 |
| 2029-12-31 | $5.62 | $6.13 | $6.97 | 1 |
| 2030-12-31 | $7.70 | $8.40 | $9.55 | 1 |
Frequently Asked Questions
What is the analyst consensus for CORT?
The consensus among 13 analysts covering Corcept Therapeutics Incorporated (CORT) is Buy with an average price target of $104.50.
What is the highest price target for CORT?
The highest price target for CORT is $145.00, set by Swayampakula Ramakanth at H.C. Wainwright on 2025-05-06.
What is the lowest price target for CORT?
The lowest price target for CORT is $35.00, set by David Amsellem at Piper Sandler on 2024-06-10.
How many analysts cover CORT?
13 analysts have issued ratings for Corcept Therapeutics Incorporated in the past 12 months.
Is CORT a buy or sell right now?
Based on 13 analyst ratings, CORT has a consensus rating of Buy (2.23/5) with a +11.2% upside to the consensus target of $104.50.
What are the earnings estimates for CORT?
Analysts estimate CORT will report EPS of $0.14 for the period ending 2026-09-30, with revenue estimated at $235M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.